E. Ohman J or Asset Management AB Acquires 1,800 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

E. Ohman J or Asset Management AB grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 225.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,600 shares of the medical research company’s stock after acquiring an additional 1,800 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Charles River Laboratories International were worth $480,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in CRL. Versant Capital Management Inc increased its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Wolff Wiese Magana LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $32,000. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. increased its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the 4th quarter worth approximately $56,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on CRL. TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Morgan Stanley dropped their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. The Goldman Sachs Group dropped their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Bank of America dropped their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $165.70 on Thursday. Charles River Laboratories International, Inc. has a twelve month low of $159.65 and a twelve month high of $275.00. The stock has a market capitalization of $8.47 billion, a price-to-earnings ratio of 20.74, a P/E/G ratio of 6.25 and a beta of 1.37. The stock has a fifty day simple moving average of $181.99 and a two-hundred day simple moving average of $194.26. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the business earned $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).